Clinical and functional features of bronchial asthma AMONG MALE ADOLESCENTS

The study is aimed at studying the clinical and functional features of BA in young men of military age. Methods. A total of 346 men aged 16–28 years (mean age 18 ± 1.7) were examined. The examination protocol corresponded to the algorithm “Medical Examination of Young Men and Draftees with Bronchial Asthma” in 2008. All patients underwent a general clinical and specific allergological examination, a functional lung examination assessing the reversibility of bronchial obstruction. Results. The diagnosis of BA was confirmed in 283 patients, and newly diagnosed in 23 (8.1%) patients. The mild BA was identified in 277 (97.9%) young men. The majority of patients - 240 (84.8%) - were in the remission phase of the disease, and 5 (1.8%) of them had a sustained remission. Allergic BA was diagnosed in the absolute majority of the examined - 261 (92.2%) people, and predominantly mild intermittent BA in 209 patients (73.8%). Symptoms of allergic rhinitis were reported by 198 (70%) patients with allergic BA and 85 (30%) patients with mixed asthma. House dust, library dust were the most common allergens. 68.2% of patients had the burdened heredity of BA and/or atopy. Most of the examined (79.9%) showed no significant changes in the respiratory function, however, 172 (60.8%) patients showed positive results of the β2-agonist test. At the time of the examination, 56 (19.8%) patients received antiasthma basic therapy, the other used only bronchodilators. Replacement of short-acting bronchodilator monotherapy for a combination of above bronchodilator and inhaled corticosteroids as an adjuvant therapy for stage 1 or 2 GINA patients ensures the early and regular administration of the baseline drug and eliminates the problem of excessive dependence on fast-acting bronchodilators. Conclusion The allergic phenotype of the disease with a predominance of milder form dominates in adolescents with asthma. Treatment with a fixed combination of beclomethasone salbutamol 250 μg/100 μg (SabaComb®) can increase compliance, improve the efficacy of the therapy and reduce the risk of BA exacerbations